Prolonged Hypercoagulability Following Major Liver Resection for Malignancy

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2028

Conditions
Hepatic DiseaseSurgery-ComplicationsHypercoagulabilityThrombosis
Interventions
DRUG

Redesca (enoxaparin sodium for injection)

Redesca is low molecular weight heparin and a biosimilar biologic drug (biosimilar) to Lovenox. Indications have been granted on the basis of similarity between Redesca and the reference biologic drug Lovenox. As such, Redesca (enoxaparin sodium) is indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield.

DRUG

Fragmin (dalteparin)

Fragmin is a low molecular weight heparin indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield. Our institution uses this drug for standard of care thromboprophylaxis (30 days) in this patient population.

Trial Locations (1)

N6A 5A5

London Health Sciences Centre, London

All Listed Sponsors
collaborator

Valeo Pharma Inc

UNKNOWN

lead

Western University, Canada

OTHER